Loader

Pathways

PathWhiz ID Pathway Meta Data

PW123625

Pw123625 View Pathway
signaling

Metabolic pathways 1572044139

Homo sapiens

PW013304

Pw013304 View Pathway
metabolic

Metabolic pathways

Mus musculus
bdnf symthesis

PW064753

Pw064753 View Pathway
metabolic

Mapa metabólico

Homo sapiens

PW124286

Pw124286 View Pathway
metabolic

Mapa metabólico

human
mapa metabólico

PW128383

Pw128383 View Pathway
drug action

Dosulepin Serotonin antagonist Action Pathway

Homo sapiens
Dosulepin is indicated in the treatment of symptoms of depressive illness, especially where an anti-anxiety effect is required. Dosulepin displays affinity towards α2-adrenoceptors and to a lesser extent, α1-adrenoceptors. Inhibition of presynaptic α2-adrenoceptors by dosulepin facilitates noradrenaline release and further potentiates the antidepressant effects. It also downregulates central β-adrenoceptors by causing a decline in the number of receptors and reduces noradrenaline-induced cyclic AMP formation. Dosulepin binds to 5HT1A and 5HT2A receptors in the cerebral cortex and hippocampus as an antagonist. 5HT1A receptors are autoreceptors that inhibit 5HT release and 5HT2A receptors are Gi/Go-coupled receptors that reduces dopamine release upon activation. Antagonism at 5HT2A receptors may also improve sleep patterns. Dosulepin also binds to muscarinic acetylcholine receptors and causes antimuscarinic side effects such as dry mouth. By acting as an antagonist at histamine type 1 (H1) receptors, dosulepin mediates a sedative effect.

PW128215

Pw128215 View Pathway
drug action

Donepezil Action Pathway

Homo sapiens
Donepezil is an acetylcholinesterase inhibitor also known as Adlarity, Aricept and Namzaric, that is used in the treatment of Alzheimer's Disease and dementia. It is administered orally or transdermally, sometimes in combination with memantine in order to treat moderate to severe dementia. Donepezil selectively inhibits the acetylcholinesterase enzyme, by doing so it is believed to enhance cholinergic transmission to relieve the symptoms of Alzheimer's and dementia. Normally acetylcholinesterase breaks down acetylcholine, this inhibited its enhances cholinergic transmission. Donepezil goes through first-pass metabolism by CYP3A4 and CYP2D6 into metabolites which can be further broken down by dealkylation, hydroxylation, oxidation, hydrolysis and glucuronidation.

PW128196

Pw128196 View Pathway
drug action

Donepezil Acetylcholinesterase Inhibitor Action Pathway

Homo sapiens
Donepezil is an acetylcholinesterase inhibitor that is used in the treatment of Alzheimer's Disease and dementia. It is administered orally or transdermally, sometimes in combination with memantine in order to treat moderate to severe dementia. Donepezil selectively inhibits the acetylcholinesterase enzyme, by doing so it is believed to enhance cholinergic transmission to relieve the symptoms of Alzheimer and dementia.

PW128386

Pw128386 View Pathway
drug action

Dolasetron Serotonin antagonist Action Pathway

Homo sapiens
Dolasetron is a selective serotonin 5-HT3 receptor antagonist. In vivo, the drug is rapidly converted into its major active metabolite, hydrodolasetron, which seems to be largely responsible for the drug's pharmacological activity. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.

PW124234

Pw124234 View Pathway
metabolic

chebulagic acid Metabolism 1602981862

Homo sapiens

PW124232

Pw124232 View Pathway
metabolic

chebulagic acid Metabolism 1602980507

Homo sapiens